DiscoverNeurology MinuteEfficacy of Atogepant in Chronic Migraine With and Without Acute Medication Overuse
Efficacy of Atogepant in Chronic Migraine With and Without Acute Medication Overuse

Efficacy of Atogepant in Chronic Migraine With and Without Acute Medication Overuse

Update: 2024-08-26
Share

Description

Dr. Tesha Monteith talks about the efficacy of atogepant for the preventive treatment of chronic migraine in participants with and without acute medication overuse.

Show reference:

https://www.neurology.org/doi/10.1212/WNL.0000000000209584 

 

Comments 
Top Podcasts
The Best New Comedy Podcast Right Now – June 2024The Best News Podcast Right Now – June 2024The Best New Business Podcast Right Now – June 2024The Best New Sports Podcast Right Now – June 2024The Best New True Crime Podcast Right Now – June 2024The Best New Joe Rogan Experience Podcast Right Now – June 20The Best New Dan Bongino Show Podcast Right Now – June 20The Best New Mark Levin Podcast – June 2024
In Channel
A General Neurologist's Practical Diagnostic Algorithm for Atypical Parkinsonian Disorders - Part 1

A General Neurologist's Practical Diagnostic Algorithm for Atypical Parkinsonian Disorders - Part 1

2024-09-2003:23

CMAP and Myosin-Loss Pathology in Patients With Critical Illness Myopathy

CMAP and Myosin-Loss Pathology in Patients With Critical Illness Myopathy

2024-09-1902:20

Improving Clinical Documentation Efficiency with AI

Improving Clinical Documentation Efficiency with AI

2024-09-1802:50

Monoclonal Antibody to PACAP for Migraine Prevention - Part 2

Monoclonal Antibody to PACAP for Migraine Prevention - Part 2

2024-09-1704:30

Depression During Intern Year Increases Risk for Persistent MD Depression: What Can Training Programs Do to Intervene

Depression During Intern Year Increases Risk for Persistent MD Depression: What Can Training Programs Do to Intervene

2024-09-1603:09

Monoclonal Antibody to PACAP for Migraine Prevention - Part 1

Monoclonal Antibody to PACAP for Migraine Prevention - Part 1

2024-09-1305:24

Association of Extent of TSS With Cerebral Glymphatic Clearance in Patients With IIH

Association of Extent of TSS With Cerebral Glymphatic Clearance in Patients With IIH

2024-09-1202:07

Effect of Ubrogepant on Patient-Reported Outcomes When Administered During the Migraine Prodrome

Effect of Ubrogepant on Patient-Reported Outcomes When Administered During the Migraine Prodrome

2024-09-1101:55

Large Study Finds COVID Vaccination Does Not Increase Multiple Sclerosis Relapses

Large Study Finds COVID Vaccination Does Not Increase Multiple Sclerosis Relapses

2024-09-1002:44

Spinal Muscular Atrophy Update in Best Practices - Part 3

Spinal Muscular Atrophy Update in Best Practices - Part 3

2024-09-0901:33

Specialist Physiotherapy for Functional Motor Disorder

Specialist Physiotherapy for Functional Motor Disorder

2024-09-0601:42

Spinal Muscular Atrophy Update in Best Practices - Part 2

Spinal Muscular Atrophy Update in Best Practices - Part 2

2024-09-0501:59

Spinal Muscular Atrophy Update in Best Practice - Part 1

Spinal Muscular Atrophy Update in Best Practice - Part 1

2024-09-0403:07

Blood Biomarkers to Detect Alzheimer Disease - Part 2

Blood Biomarkers to Detect Alzheimer Disease - Part 2

2024-09-0301:47

Outcomes of Patients With MCI With Lewy Bodies or Alzheimer Disease - Part 2

Outcomes of Patients With MCI With Lewy Bodies or Alzheimer Disease - Part 2

2024-09-0201:38

Blood Biomarkers to Detect Alzheimer Disease - Part 1

Blood Biomarkers to Detect Alzheimer Disease - Part 1

2024-08-3001:41

Outcomes of Patients With MCI With Lewy Bodies or Alzheimer Disease - Part 1

Outcomes of Patients With MCI With Lewy Bodies or Alzheimer Disease - Part 1

2024-08-2901:12

New Treatment Option for Parkinson Disease

New Treatment Option for Parkinson Disease

2024-08-2802:33

Chronic Adaptive Deep Brain Stimulation Versus Conventional Stimulation in Parkinson Disease

Chronic Adaptive Deep Brain Stimulation Versus Conventional Stimulation in Parkinson Disease

2024-08-2703:07

Efficacy of Atogepant in Chronic Migraine With and Without Acute Medication Overuse

Efficacy of Atogepant in Chronic Migraine With and Without Acute Medication Overuse

2024-08-2602:03

loading
Google Play
Download from Google Play
Castbox
Download from App Store
usUnited States
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Efficacy of Atogepant in Chronic Migraine With and Without Acute Medication Overuse

Efficacy of Atogepant in Chronic Migraine With and Without Acute Medication Overuse

American Academy of Neurology